Intravenous immunoglobulin and autoimmunity

Israel Medical Association Journal

Volumn 12, Issue 1, 2010, Pages 45-46

  Zandman Goddard, Gisele ^a,b  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Intravenous immunoglobulin; IVIG; Mixed cryoglobulinemia; Systemic lupus erythematosus; Vasculitis

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; CD16 ANTIGEN; COMPLEMENT; CYTOKINE; FC RECEPTOR IIB; IMMUNOGLOBULIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ACUTE KIDNEY FAILURE; ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANAPHYLAXIS; ANTIPHOSPHOLIPID SYNDROME; ARTHRALGIA; ARTHRITIS; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; B LYMPHOCYTE; BACKACHE; BLOOD DISEASE; BLOOD PRESSURE; CHEST TIGHTNESS; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CRYOGLOBULINEMIA; CYTOMEGALOVIRUS INFECTION; DERMATOMYOSITIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG COST; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; EDITORIAL; ENTERITIS; FATIGUE; FEVER; FLUSHING; GUILLAIN BARRE SYNDROME; HASHIMOTO DISEASE; HEADACHE; HEART DISEASE; HEPATITIS C; HUMAN; HYPONATREMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLAMMATORY DISEASE; INNATE IMMUNITY; KIDNEY DISEASE; LOW DRUG DOSE; MALAISE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYALGIA; MYASTHENIA GRAVIS; MYOCARDITIS; NAUSEA; NEOPLASM; NEPHRITIS; NEUROLOGIC DISEASE; NEUTROPENIA; PANCYTOPENIA; PEMPHIGUS VULGARIS; PERICARDITIS; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; POLYARTERITIS NODOSA; POLYMYOSITIS; PSEUDO HYPONATREMIA; PSYCHOSIS; PURE RED CELL ANEMIA; PURPURA; RELAPSE; REMISSION; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOEMBOLISM; VASCULITIS; VOMITING; VON WILLEBRAND DISEASE;

AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS;

EID: 76049118982     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (20)

1. Shoenfeld Y, Zandman-Goddard G, Stojanovich L, et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases - 2008. IMAJ Isr Med Assoc J 2008; 10: 8-12.
2. Almog O, Berlin T, Rotman-Pikielny P, Levy Y. A dramatic response to intravenous immunoglobulin in a patient with mixed cryoglobulinemia. IMAJ Isr Med Assoc J 2010; 12: 53-54.
3. Seite JF, Shoenfeld Y, Youinou P, Hillion S. What is the contents of the magic draft IVIg? Autoimmun Rev 2008; 7: 435-9.
4. Sapir T, Blank M, Shoenfeld Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann NY Acad Sci 2005; 1051: 743-78.
5. Nussinovitch U, Shoenfeld Y. Intravenous immunoglobulin - indications and mechanisms in cardiovascular diseases. Autoimmun Rev 2008; 7: 445-52.
6. Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serological response. Lupus 1999; 8: 705-12.
7. Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 2005; 29: 219-28.
8. Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney - a two-edged sword. Semin Arthritis Rheum 2004; 34: 593-601.
9. Griffin JW, Hughes RAC. Intravenous immunoglobulin for neuromuscular disease: costs, benefits and reimbursement. Nature Clin Pract Neurol 2009; 5: 119.
10. Levy Y, Uziel Y, Zandman-Goddard G, et al. Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann NY Acad Sci 2005; 1051: 779-86.
11. Martinez V, Cohen P, Pagnoux C. Intravenous immunoglobulin for relapses of systemic vasculitides associated with antineutrophilic cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008; 58: 308-17.
12. Sherer Y, Kuechler S, Scali JJ, et al. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 Cases. IMAJ Isr Med Assoc J 2008; 10: 55-7.
13. Shoenfeld Y, Rauova L, Gilburd B, et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 2002; 14: 1303-11.
14. Blank M, Anafi L, Zandman-Goddard G, et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 2007; 19: 857-65.
15. Zandman-Goddard G, Blank M, Shoenfeld Y. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. Lupus 2009; 18: 884-8.
16. von Gunten S, Simon HU. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun Rev 2008; 7: 453-6.
17. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin - adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29: 173-84.
18. Sherer Y, Levy Y, Langevitz P, Rauova L, Fabbrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 2001; 62: 133-7.
19. Zandman-Goddard G, Krauthammer A, Shoenfeld Y. The steroid-sparing effect of IVIG. Exp Rev Clin Immunol 2007; 3: 773-80.
20. Agmon-Levine N, Ram M, Barzilai O, et al. Prevalence of hepatitis C serum antibody in autoimmune diseases. J Autoimmunity 2009; 32: 261-6.